A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors

NCT05129280 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

23

Enrollment

INDUSTRY

Sponsor class

Stopped The study was terminated due to program discontinuation.

Conditions

Solid Tumors

Interventions

DRUG: RO7444973
DRUG: Tocilizumab

Sponsor

Hoffmann-La Roche